Skip to Content

Drug interactions between Bridion and ethinyl estradiol / segesterone

Results for the following 2 drugs:
Bridion (sugammadex)
ethinyl estradiol/segesterone

Interactions between your drugs


sugammadex segesterone

Applies to: Bridion (sugammadex) and ethinyl estradiol / segesterone

Consumer information for this interaction is not currently available.

ADDITIONAL CONTRACEPTION RECOMMENDED: Sugammadex may decrease the free plasma concentrations and therapeutic efficacy of hormonal contraceptives. In vitro binding studies indicate that sugammadex can bind to progestogen. Sugammadex 4 mg/kg is predicted to reduce progestogen systemic exposure (AUC) by 34%. The predicted effect is lower for estrogens. According to the manufacturer, the administration of a bolus dose of sugammadex may result in reduced contraceptive effectiveness equivalent to a missed dose of the contraceptive. Clinical data have not been reported.

MANAGEMENT: Female patients of reproductive potential receiving hormonal contraceptives (whether oral or non-oral) should use an additional, nonhormonal contraceptive method or backup method of contraception (e.g., condoms and spermicides) for 7 days after sugammadex administration.


  1. "Product Information. Bridion (sugammadex)." Merck & Company Inc, Whitehouse Station, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Drug and food interactions


segesterone food

Applies to: ethinyl estradiol / segesterone

Consumer information for this interaction is not currently available.

MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.


ethinyl estradiol food

Applies to: ethinyl estradiol / segesterone

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

For clinical details see professional interaction data.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.